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SequencingWhole genome sequencing studies have identiﬁed several oncogenic mutations in multiple myeloma (MM). As
MM progresses, it evolves genetically underscoring the need to have tools for rapid detection of targetable mu-
tations to optimize individualized treatment. Massachusetts General Hospital (MGH) has developed a Clinical
Laboratory Improvement Amendments (CLIA)-approved, high-throughput, genotyping platform to determine
the mutation status of a panel of known oncogenes. Sequence analysis using SNaPshot on DNA extracted from
bone marrow and extramedullary plasmacytomas is feasible and leads to the detection of potentially druggable
mutations. Screening MM patients for somatic mutations in oncogenes may provide novel targets leading to ad-
ditional therapies for this patient population.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. IntroductionOver the last 10 years, the availability of effective new drugs with
acceptable toxicity, such as the immunomodulatory drugs (IMiDs) and
the proteasome inhibitors have modiﬁed the traditional treatment
paradigms in patients with multiple myeloma (MM) with an improve-
ment in the quality and the duration of life (Dimopoulos et al., 2007;
Richardson et al., 2014; Jagannath et al., 2004; Richardson et al., 2003,
2005). Despite these advances, these therapies are non-speciﬁc with
pleiotropicmechanisms of action that do not target speciﬁc genetic mu-
tations. This is due, in part, to the complex genetic architecture of the
disease that has, thus far, not been amenable to targeted approaches.
Themolecular pathogenesis ofMM is complex and incompletely un-
derstood. While it is known that there are characteristic chromosomal
translocations resulting in over-expression of genes by juxtaposition
to the immunoglobulin heavy chain (Ig) locus, these abnormalities can-
not fully account for the malignant transformation to MM as many are
found in the pre-malignant disease state, monoclonal gammopathy of
undetermined signiﬁcance (MGUS). Mutations and deregulation can
occur through diverse pathways. Translocations that place oncogenes
under the strong enhancers of the IgH loci, lead to deregulation of the
G1 to S transition. Gains and losses of deoxyribonucelic acid (DNA)
cause copy number alterations that lead to loss of cell cycle regulators
(Morgan et al., 2012). Hyperploidy is associated with increased geneeneral Hospital, 55 Fruit Street,
. This is an open access article underexpression and with activating mutations in driver oncogenes. Finally,
genetic mutations may also drive deregulation. Though there are few
recurrently mutated genes, several of those identiﬁed fall within com-
monpathways. Speciﬁcally,mutations inNRAS,KRAS and BRAF fall with-
in the extracellular signal-regulated kinase (ERK) pathway (Morgan
et al., 2012).
In 2011, Chapman and colleagues published the results of genome
sequencing for 38 patients with MM (Chapman et al., 2011). In nearly
50% of patients, mutations were found in genes involving ribonucleic
acid (RNA) processing, protein translation and the unfolded protein re-
sponse. Notably, 16 out of 38 patients had mutations affecting protein
translocation and homeostasis highlighting these as therapeutic targets.
Statistically signiﬁcant protein-coding mutations identiﬁed included
NRAS, KRAS, FAM46C, DIS3, TP53, CCND1, PNRC1, ALOX12B, HLA-A, and
MAGED1. In addition, one patient had a BRAF kinase mutation (G469A)
prompting genotyping of an additional 161 MM samples for the 12
most common BRAFmutations. Seven additional patients were identi-
ﬁed with BRAFmutations (4%), a druggable target. More recently, Lohr
and colleagues performed parallel sequencing of paired and normal
samples from 203 MM patients. Similar to Chapman, frequent muta-
tions were observed in KRAS, NRAS, BRAF, FAM46C, TP53, and DIS3
(Lohr et al., 2014). Tumors demonstrated signiﬁcant heterogeneity
with the presence of mutations often in subclonal populations andmul-
tiple mutations within the same pathway within the same patient.
MM evolves and invariably progresses through therapy. Bolli and
colleagues recently published results of whole-exome sequencing,
copy-number proﬁling, and cytogenetics of myeloma samples, includ-
ing serial samples in 15 patients, which demonstrated complex clonalthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
Table 1
Patient characteristics.
Characteristics Wild type
(n = 41)
Mutated
(n = 26)
P value
ISS stage at diagnosis, n (%)
I 15 (36.6) 9 (34.6) 1.00
II 11 (26.8) 6 (23.1)
III 14 (34.1) 9 (34.6)
Unknown 1 (2.4) 2 (7.7)
Median age at Dx, years (range) 64 (38–83) 60 (47–74) 0.46
M-protein, n (%)
IgG K 11 (26.8) 9 (34.6) 0.15
IgG L 6 (14.6) 6 (23.1)
IgA K 6 (14.6) 4 (15.4)
IgA L 3 (7.3) 5 (19.2)
K light 9 (22.0) 1 (3.8)
L light 6 (14.6) 1 (3.8)
Heavy chain 26 (63.4) 24 (92.3) 0.009
Light chain 15 (36.6) 2 (7.7)
Timing of SNaPshot, n (%)
Upfront 9 (22.0) 3 (11.5) 0.34
Relapse 32 (78.0) 23 (88.5)
Med. no of prior Tx (range) 2 (1–7) 4 (1–7) 0.07
ASCT, n (%) 18 (56.3) 15 (65.2) 0.58
Lenalidomide, n (%) 29 (90.6) 22 (95.7) 0.63
Bortezomib, n (%) 29 (90.6) 22 (95.7) 0.63
Cyclophosphamide, n (%) 18 (56.3) 20 (87.0) 0.02
ASCT— autologous stem cell transplant.
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clonal and subclonal heterogeneity within the same patient without
the predominant clone necessarily translating at the messenger RNA
(mRNA) level. These and other studies demonstrate the complexity of
theMMgenome underscoring a need for rapid identiﬁcation of possible
druggable oncogenic mutations in order to customize therapy for MM
patients.
We have developed a Clinical Laboratory Improvement Amend-
ments (CLIA)-approved, high-throughput, genotyping platform to de-
termine the mutation status of a large panel of known cancer genes.
The mutation detection protocol, SNaPshot, uses a highly sensitive
multiplexed polymerase chain reaction (PCR)-based assay to simulta-
neously identify 70 genetic loci frequently mutated in 15 cancer
genes. This assay has been used at our institution for over 4 years for
tumor genotyping and to help guide therapeutic decisions for patients
with various malignancies. We performed SNaPshot analysis on 67
bone marrow samples from MM patients after isolating genomic DNA
from these samples after performing quality assurance tests.
2. Methods
2.1. Patients and Samples
Patients diagnosed with MM and treated at the MGH Cancer Center
between 2011 and 2013 who had SNaPshot testing were identiﬁed. All
subjects voluntarily signed informed consent approved by the institu-
tional review board for SNaPshot testing.
2.2. Genotype Analysis
Nucleic acids were extracted from bone marrow samples obtained
from myeloma patients using the automated QIAcube system (Qiagen)
without any plasma cells. We required 10% of the cells to be malignant
MM cells for SNaPshot testing, given the assay sensitivity of overall 5%,
as if all 10% clonal plasma cells were carrying themutation, themutated
allele fraction would be exactly 5%. Multiplexed mutational analysis
queried for 152 hotspot mutations distributed across 15 cancer genes,
including AKT1, APC, BRAF, CTNNB1, EGFR, FLT3, ERBB2, IDH1, IDH2,
JAK2, KIT, KRAS, MAP2K1, NOTCH1, NRAS, PIK3CA, PTEN, and TP53
(Supp. Table 1) was performed using a custom modiﬁed ABI PRISM®
SNaPshot™Multiplex System on an ABI PRISM 3730 DNA Analyzer, as
previously described (Dias-Santagata et al., 2010, 2011). The data
were interpreted with GeneMapper Analysis Software (Life Technolo-
gies/Applied Biosystems). Testing of the tumor suppressor genes TP53,
APC and PTEN was limited to common mutation sites, covering 29%,
15% and 15%, respectively, of all known somatic mutations in these
genes. Patientswere classiﬁed according towhether any of the 15 tested
genes were mutated versus wild type.
2.3. Statistical Analysis
The distributions of clinical variables in patients with wild type ver-
sus mutated tumors were compared using Fisher's exact test (categori-
cal variables) and Wilcoxon rank sum test (continuous variables).
Median survival for the whole group and by mutation status (mutation
vs. wild type) was calculated using the Kaplan–Meier method and the
log-rank test was used to compare survival by mutation status.
3. Results
The majority (55/67) of samples taken were at time of relapse.
However, it is noteworthy that 3/12 specimens obtained in the upfront
setting did have oncogenic mutations. When comparing samples of pa-
tients with mutations versus those without, there were no signiﬁcant
differences between stage at diagnosis, age, and type of heavy chain
monoclonal protein (Table 1). Themajority ofmutationswere observedin patients with heavy chain disease (24/26). Patients with mutations
had a median of 4 prior lines of therapy versus 2 in wild type patients
(p = 0.03). When baseline cytogenetics were compared between re-
lapsed patients with mutations versus wild type, no signiﬁcant differ-
ences were appreciated.
Thirty-nine % (26/67) of tumor samples from 67 unique patients har-
bored candidatemutations. 3/26were BMsamples fromnewlydiagnosed
patients and 23/26were bonemarrow (22/26) and plasmacytoma (1/26)
samples from relapsedMM. All samples withmutations had singlemuta-
tions. Somatic oncogenic mutations were found in KRAS (15), NRAS (6),
BRAF (2), TP53 (2), and HRAS (1) (Table 2).
4. Discussion
Clinical grade sequence analysis using SNaPshot on DNA extracted
from bone marrow and extramedullary plasmacytomas is feasible and
leads to the detection of potentially druggable mutations. Mutations
were found in 39% (26/67) of patients in our 67-patient cohort. Al-
thoughwhole exome orwhole genome sequencing is possible in the re-
search laboratory, the routine use of thesemethods in clinical practice is
time and cost-limited. SNaPshot provides a rapid, reasonable-cost
method of identifying oncogenic mutations in MM patient samples. A
limitation of this technology is that only pre-identiﬁedmutations are lo-
cated and that other mutations not included in SNaPshot could poten-
tially be missed. This likely resulted in a lower incidence of mutations
in our patient population. Additionally, our assay was performed on
unpuriﬁed MM cells and this may contribute to a higher false negative
rate in our assay and is a limitation of the study. This is in contrast
with a new SNaPshot NGS assay that the Center for Integrated Diagnos-
tic has developed at our institution which is a targeted next generation
sequencing assay and is not amplicon based. Our next generation test,
the SNaPshot NGS assay, fully sequences 1000 cancer genes. This assay
utilizes a multiplex PCR technology called Anchored Multiplex PCR for
single nucleotide variant and insertion/deletion (indel) detection in ge-
nomic DNA using next generation sequencing. This assay has actually
similar sensitivity to the SNaPshot multiplexed amplicon based assay
(5%), but is quantitative and therefore allows for the calculation of the
mutational load. Furthermore, the new assay although targeted, se-
quences entire exons and not just a few hotspot nucleotides, allowing
for detection of additional mutations. One of the strengths of having
Table 2
Mutations detected by SNaPshot.
Mutation n = 67
KRAS (n = 15) 15 (22.4)
c.183A N C (p.Q61H) 4
c.35G N A (p.G12D) 3
c.34G N C (p.G12R) 2
c.34G N T (p.G12C) 2
c.35G N C (p.G12A) 2
c.34G N A (p.G12S) 1
c.35G N T (p.G12V) 1
NRAS (n = 6) 6 (8.9)
c.38G N A (p.G13D) 2
c.183A N C (p.Q61H) 2
c.182A N G (p.Q61R) 1
c.35G N A (p.G12N) 1
HRAS (n = 1) 1 (1.5)
c.181 C N A (p.Q61K) 1
BRAF (n = 2) 2 (3)
c.1799 T N A (p.V600E) 1
c.1406G N A (p.G469E) 1
p53 (n = 2) 2 (3)
c.743G N A (p.R248G) 1
c.818G N A (p.R273H) 1
Wild type 41 (61.2)
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as new critical targets emerge. Costlier and lengthier commercially
available testing does not necessarily provide therapeutic guidance. By
focusing our analysis to thesemost relevant targets, we can signiﬁcantly
reduce costs and turnaround time, aswell as provide results to clinicians
that offer the clearest implications for best treatment options for that
patient.
The understanding of the clinical implications of somatic mutations
in MM is an evolving ﬁeld. Several mutated oncogenes were found in
our cohort of MM specimens including KRAS, NRAS, BRAF, and TP53. In
the era of personalizedmedicine, the availability of rapid, high through-
put genomic sequencing opens up the possibility of efﬁciently integrat-
ing genomic analysis into our clinical practice. Case reports of success
with targeted therapy for BRAF mutations in MM provide a foundation
of optimism in support of further investigation (O'Donnell & Raje,
2013). There is currently an open-label, phase II study of vemurafenib
in patients with BRAF V600 mutation-positive cancers which includes
myeloma patients (NCT01524978). Mulligan and colleagues recently
reported that NRAS mutations were associated with lower response
rates to single-agent bortezomib but not to high dose dexamethasone,
an association that was not found in patients with KRASmutations. Fur-
therwork is needed to understand if the impact of NRAS is drug-speciﬁc
but their work does highlights the importance of understanding the re-
lationship ofmutationswith response to therapy (Mulligan et al., 2014).However, as Lohr and colleagues discuss, the clinical beneﬁt of targeted
therapies in a tumor deﬁned by subclonality may prove challenging
(Lohr et al., 2014). Effective targeted therapy may require a better un-
derstanding of the extent of clonal heterogeneity. Having a technology
that can facilitate this understanding may prove valuable in the further
development of effective targeted therapies. Future strategies of treat-
ment may include the combination of targeted therapies with existing
proteosome inhibitors and immunomodulatory drugs. This analysis
highlights the feasibility of integrating rapid genomic analysis into clin-
ical practice.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2014.11.008.
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